Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate CMX-2043 for prevention of renal and cardiac
injury associated with coronary angiography in patients with acute coronary syndrome (ACS),
but excluding ST-elevation myocardial infarction (STEMI) patients. This study will
specifically examine the ability of CMX-2043 to prevent acute renal injury following coronary
angiography. The study will also examine the ability of CMX 2043 for prevention of
periprocedural cardiac injury. Information will be obtained relating to the ability of CMX
2043 for prevention of major adverse cardiac and renal events following the procedure.
Additional information will be obtained in this study to evaluate safety of the drug. Dose
and regimen information will also be obtained for future clinical studies of CMX-2043.